Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940676 | 0.81 | ALDH1A1 (0.34) | HPGDERN1 | |
| SCHEMBL31140494 | 0.73 | MCL1 (0.42) | NPC1RAB9AHPGDSMN1; SMN2ERN1 | |
| SCHEMBL31140501 | 0.72 | DGAT1 (0.39) | IDO1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL20267758 | 0.72 | IDO1 (0.33) | IDO1 | |
| SCHEMBL25280044 | 0.71 | LMNA (0.40) | NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL192353 | 0.71 | CES2 (0.32) | ERN1 | |
| SCHEMBL5802926 | 0.71 | HTR2A (0.32) | IDO1 | |
| SCHEMBL27219925 | 0.69 | CA1 (0.33) | — | |
| SCHEMBL10147778 | 0.69 | PLAU (0.34) | IDO1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL7902786 | 0.68 | HDAC1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-8592426-B2 | Aryl-benzocycloalkyl amide derivatives | Hoffmann—La Roche Inc. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| CN-103328436-A | Novel aryl-benzocycloalkylamide derivatives | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| CN-103249727-A | New biaryl amide derivatives | HOFFMANN LA ROCHE | 2013-08-14 | — | — | CN | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | IDO1 1099/4885NPC1 2184/4885RAB9A 13/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | IDO1 1555/4885NPC1 887/4885RAB9A 68/4885 |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | IDO1 1099/4885NPC1 2184/4885RAB9A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.